172 related articles for article (PubMed ID: 26075254)
1. Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines.
Baba Y; Fujii M; Maeda T; Suzuki A; Yuzawa S; Kato Y
Biomed Res Int; 2015; 2015():657179. PubMed ID: 26075254
[TBL] [Abstract][Full Text] [Related]
2. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
[TBL] [Abstract][Full Text] [Related]
3. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
[TBL] [Abstract][Full Text] [Related]
4. Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.
Yang YL; Ji C; Bi ZG; Lu CC; Wang R; Gu B; Cheng L
PLoS One; 2013; 8(1):e54736. PubMed ID: 23372762
[TBL] [Abstract][Full Text] [Related]
5. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells.
Chun KH; Kosmeder JW; Sun S; Pezzuto JM; Lotan R; Hong WK; Lee HY
J Natl Cancer Inst; 2003 Feb; 95(4):291-302. PubMed ID: 12591985
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
7. [Effects of deguelin on proliferation and apoptosis of MCF-7 breast cancer cells by phosphatidylinositol 3-kinase/Akt signaling pathway].
Chu ZH; Liang XH; Zhou XL; Huang RF; Zhan Qz; Jiang JW
Zhong Xi Yi Jie He Xue Bao; 2011 May; 9(5):533-8. PubMed ID: 21565140
[TBL] [Abstract][Full Text] [Related]
8. Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2011 Dec; 129(12):2916-27. PubMed ID: 21472727
[TBL] [Abstract][Full Text] [Related]
9. Icariside II induces apoptosis via inhibition of the EGFR pathways in A431 human epidermoid carcinoma cells.
Wu J; Zuo F; Du J; Wong PF; Qin H; Xu J
Mol Med Rep; 2013 Aug; 8(2):597-602. PubMed ID: 23807305
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of deguelin-induced apoptosis in transformed human bronchial epithelial cells.
Lee HY
Biochem Pharmacol; 2004 Sep; 68(6):1119-24. PubMed ID: 15313408
[TBL] [Abstract][Full Text] [Related]
12. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
13. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin.
Jin Q; Feng L; Behrens C; Bekele BN; Wistuba II; Hong WK; Lee HY
Cancer Res; 2007 Dec; 67(24):11630-9. PubMed ID: 18089792
[TBL] [Abstract][Full Text] [Related]
14. Deguelin, an Akt inhibitor, down-regulates NF-κB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice.
Kang HW; Kim JM; Cha MY; Jung HC; Song IS; Kim JS
Dig Dis Sci; 2012 Nov; 57(11):2873-82. PubMed ID: 22623043
[TBL] [Abstract][Full Text] [Related]
15. A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.
Suh YA; Kim JH; Sung MA; Boo HJ; Yun HJ; Lee SH; Lee HJ; Min HY; Suh YG; Kim KW; Lee HY
Cancer Lett; 2013 May; 332(1):102-9. PubMed ID: 23348700
[TBL] [Abstract][Full Text] [Related]
16. Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.
Axelrod MJ; Mendez RE; Khalil A; Leimgruber SS; Sharlow ER; Capaldo B; Conaway M; Gioeli DG; Weber MJ; Jameson MJ
Head Neck; 2015 Dec; 37(12):1722-32. PubMed ID: 24986420
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
[TBL] [Abstract][Full Text] [Related]
18. Deguelin exerts anticancer activity of human gastric cancer MGC-803 and MKN-45 cells in vitro.
Kang W; Zheng X; Wang P; Guo S
Int J Mol Med; 2018 Jun; 41(6):3157-3166. PubMed ID: 29512685
[TBL] [Abstract][Full Text] [Related]
19. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.
Bancroft CC; Chen Z; Yeh J; Sunwoo JB; Yeh NT; Jackson S; Jackson C; Van Waes C
Int J Cancer; 2002 Jun; 99(4):538-48. PubMed ID: 11992543
[TBL] [Abstract][Full Text] [Related]
20. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
Mehta R; Katta H; Alimirah F; Patel R; Murillo G; Peng X; Muzzio M; Mehta RG
PLoS One; 2013; 8(6):e65113. PubMed ID: 23762292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
